Bone Grafts Research Today is a free monthly online journal that collates and summarizes the latest research about Bone Grafts, including details on spine fusion, surgery, procedure, risks.

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.

Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD

INSERM U430 and Université Pierre et Marie Curie (UPMC-Paris 6), Hôpital Broussais, 96 Rue Didot, 75014, Paris, France.

Intravenous immunoglobulin (IVIg) has been used in the treatment of primary and secondary antibody deficiencies for over two decades. Since the early 1980s, the therapeutic efficacy of IVIg has been established in idiopathic thrombocytopenic purpura, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, dermatomyositis and Kawasaki syndrome, and the prevention of graft versus host disease in recipients of allogeneic bone marrow transplants. Its use has also been reported in a large number of other autoimmune and systemic inflammatory conditions. In this review, we discuss the mechanisms by which IVIg exerts immunomodulatory effects in immune pathologies.

Published 19 December 2005 in Clin Exp Med, 5(4): 135-40.
Full-text of this article is available online (may require subscription).

© 2004-2008 Bone Grafts Research Today. All Rights Reserved.